0001165527-16-000850.txt : 20160804 0001165527-16-000850.hdr.sgml : 20160804 20160804120741 ACCESSION NUMBER: 0001165527-16-000850 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 36 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160804 DATE AS OF CHANGE: 20160804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MCPI, INC. CENTRAL INDEX KEY: 0001516559 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 450704149 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-54770 FILM NUMBER: 161806476 BUSINESS ADDRESS: STREET 1: 817 NW HILL STREET CITY: BEND STATE: OR ZIP: 97701 BUSINESS PHONE: 214-666-8364 MAIL ADDRESS: STREET 1: 817 NW HILL STREET CITY: BEND STATE: OR ZIP: 97701 FORMER COMPANY: FORMER CONFORMED NAME: Med-Cannabis Pharma, Inc. DATE OF NAME CHANGE: 20140702 FORMER COMPANY: FORMER CONFORMED NAME: SW China Imports, Inc. DATE OF NAME CHANGE: 20110324 10-Q/A 1 g8274.htm g8274.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC  20549

Form 10-Q/A
(Amendment No. 1)

 
(Mark one)
x
Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934
   
 
For the quarterly period ended March 31, 2016
   
o
Transition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934
   
 
For the transition period from ______________ to _____________
 

Commission File Number: 000-54770
 
 
MCPI, Inc.
(Exact name of registrant as specified in its charter)
 
Nevada
45-0704149
(State of incorporation)
(IRS Employer ID Number)
 
454 SW Coast Highway, Newport, OR 97365
(Address of principal executive offices)
 
(214) 666-8364
(Issuer’s telephone number)

 
Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES  x  NO  o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES  x  NO  o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o
Accelerated filer o
Non-accelerated filer o
Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): YES  o  NO  x
 
State the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date: August 1, 2016: 50,220,000 shares of common stock, par value $0.001
 

 
 

 

MCPI, Inc.
AMENDMENT NO. 1 TO THE QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2016

EXPLANATORY NOTE

The purpose of this Amendment No. 1 to our Quarterly Report on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on August 2, 2016 is to furnish Exhibits 101 to the Form 10-Q.
 
No changes have been made to the Quarterly Report other than the furnishing of Exhibit 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB and 101.PRE described above. This Amendment No. 1 to Form 10-Q does not reflect subsequent events occurring after the original filing date of the Form 10-Q or modify or update in any way disclosures made in the Form 10-Q, as amended.


 
Part II - Other Information

Item 6 - Exhibits

31.1
Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002 - Chief Executive and Financial Officer (+)
32.1
Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002 - Chief Executive and Financial Officer (+)
101
Interactive data files pursuant to Rule 405 of Regulation S-T.

(+) - previously filed
 

 
SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
   
MCPI, Inc.
     
     
     
Dated: August 4, 2016
 
/s/ R.Wayne Duke
   
R.Wayne Duke
   
Chief Executive and Financial Officer
 
 
 
2

 
EX-101.INS 2 mcpi-20160331.xml 0001516559 2016-01-01 2016-03-31 0001516559 2016-08-01 0001516559 us-gaap:CommonStockMember 2014-12-31 0001516559 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001516559 2015-12-31 0001516559 2016-03-31 0001516559 2015-01-01 2015-03-31 0001516559 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001516559 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001516559 us-gaap:CommonStockMember 2015-12-31 0001516559 us-gaap:CommonStockMember 2016-03-31 0001516559 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001516559 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001516559 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001516559 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001516559 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001516559 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001516559 us-gaap:RetainedEarningsMember 2014-12-31 0001516559 us-gaap:RetainedEarningsMember 2015-12-31 0001516559 us-gaap:RetainedEarningsMember 2016-03-31 0001516559 2015-01-01 2015-12-31 0001516559 2014-12-31 0001516559 2015-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares MCPI, Inc. 0001516559 10-Q 2016-03-31 false --12-31 No No Yes Smaller Reporting Company Q1 2016 50220000 1100000 0 0 0 0 769923 811540 607314 685851 59846 59846 20947 20140 0 0 50170 59021670 -769923 -811540 50220 50220 59336620 59336620 -59418274 -60156762 -60198380 -346434 -60156763 -60198380 59336620 59336620 50220 50220 0.001 0.001 25000000 25000000 0 0 0 0 0.001 0.001 500000000 500000000 50170000 50220000 50170000 50220000 -17730 -440457 17730 440457 122621 17730 317836 -41617 -449272 -41617 -449272 -738488 -41617 -738488 -41617 -449272 -23887 -8815 -0.00 -0.01 50220000 50206111 50170000 50220000 50220000 300000 300000 -18537 -121403 -5000 23080 10143 7726 -4403 18537 117000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The components of income tax (benefit) expense for the each of the three months ended March 31, 2016 and 2015, respectively, are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">T<b>hree months</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Three months</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>ended</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>ended</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>March 31,</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>March 31,</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Federal:</font></td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 72%; padding-left: 9pt"><font style="font-size: 10pt">Current</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-size: 10pt">Deferred</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">State:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt"><font style="font-size: 10pt">Current</font></td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-size: 10pt">Deferred</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt"><font style="font-size: 10pt; letter-spacing: 9pt">&#160;&#160;&#160;</font><font style="font-size: 10pt">&#160;Total</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's income tax (benefit) expense for the each of the three months ended March 31, 2016 and 2015, respectively, are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Three months</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Three months</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>ended</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>ended</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>March 31,</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>March 31,</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 72%"><font style="font-size: 10pt">Statutory rate applied to income before income taxes</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">(14,000</font></td> <td nowrap="nowrap" style="width: 1%"><font style="font-size: 10pt">)</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">(152,800</font></td> <td nowrap="nowrap" style="width: 1%"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Increase (decrease) in income taxes resulting from:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt"><font style="font-size: 10pt">State income taxes</font></td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt"><font style="font-size: 10pt">Other, including reserve for deferred tax asset</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-size: 10pt">and application of net operating loss carryforward(s)</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">14,000</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">152,800</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt"><font style="font-size: 10pt; letter-spacing: 9pt">&#160;&#160;&#160;</font><font style="font-size: 10pt">&#160;Income tax expense</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Temporary differences, consisting primarily of the prospective usage of net operating loss carryforwards give rise to deferred tax assets and liabilities as of March 31, 2016 and December 31, 2015, respectively:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>March 31,</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td> <td><b>&#160;</b></td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td> <td nowrap="nowrap"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Deferred tax assets</font></td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 72%; padding-left: 9pt"><font style="font-size: 10pt">Net operating loss carryforwards</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">399,000</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">385,000</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font-size: 10pt">Less valuation allowance</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(399,000</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(385,000</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 3pt"><font style="font-size: 10pt; letter-spacing: 9pt">&#160;&#160;&#160;</font><font style="font-size: 10pt">&#160;Net Deferred Tax Asset</font></td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">MCPI, Inc. (&#147;Company&#148; or &#147;Med-Cannabis Pharma&#148;) was incorporated under the laws of the State of Nevada on February 23, 2011.&#160;&#160;The Company was originally incorporated as Southwest China Imports, Inc. on February 23, 2011 in the State of Nevada.&#160;&#160;The Company&#146;s initial business plan was to import high-end handmade lace wigs, hairpieces, and other beauty supplies and accessories manufactured overseas into the United States.&#160;&#160;In June 2014, the Company changed its name to Med-Cannabis Pharma, Inc. and implemented a new business plan to enter into the retail sale of medical and personal use&#160;&#160;marijuana, where allowable.&#160;&#160;In October 2015, the Company changed its name to MCPI, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective March 31, 2016, the Company ceased activities in all of its subsidiaries and disposed of Med-Pharma Management, Inc. and High Desert MMJ, Inc.&#160;&#160;Prior thereto, the Company&#146;s&#160;&#160;subsidiaries were Medical Management Systems, Inc., an Oregon corporation engaged in providing back-office and support services to marijuana dispensaries in the State of Oregon; Med-Pharma Management, Inc., a Washington State corporation which was formed to own, manage or provide back-office and support services to marijuana dispensaries in Washington State; and High Desert MMJ, Inc. an Oregon corporation, which is a 99.0% partner in Emerald Mountain Organics, an Oregon joint venture, formed to facilitate the development and growing of medical marijuana plants for wholesale distribution to licenced dispensaries in the State of Oregon.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2015, Medical Management Systems, Inc. held a Management Contract for three marijuana dispensaries located in Newport, Bend and Cottage Grove, Oregon; which are owned by a company controlled by a related party.&#160;&#160;This Management Contract was terminated by the consent of both parties, effective March 31, 2016.&#160;&#160;&#160;Med-Pharma only conducted introductory due diligence efforts in the State of Washington and, currently, had abandoned all activities in the State of Washington.&#160;&#160;Emerald Mountain Organics had, as of September 30,2015, established an early-phase growing operation and has generated nominal sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the first 10 days of October 2015, the Company&#146;s subsidiary, High Desert MMJ, Inc., learned that the 1.0% minority partner in the Emerald Mountain Organics joint venture had absconded with all of the assets of the joint venture.&#160;&#160;Efforts to locate and recover either the individuals representing said 1.0% minority partner or the said absconded assets were unsuccessful.&#160;&#160;Accordingly, effective October 10, 2015, High Desert MMJ, Inc. abandoned the Emerald Mountain Organics joint venture and wrote off said investment.&#160;&#160;The cumulative start-up losses in the Company&#146;s consolidated financial statements for the Emerald Mountain Organics joint venture, through the date of abandonment were approximately $53,000 and the Company recognized a loss on the stolen assets of approximately $51,000 during the quarter ended December 31, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 1, 2016, the Company entered into a Settlement, General and Mutual Release of Claims and Assignment of Interest Transfer Agreement (Settlement Agreement) with its majority shareholder and a related party.&#160;&#160;The Settlement Agreement relates to the Company&#146;s management of three medical marijuana dispensaries (Stores) located in Oregon, which are owned by Bendor Investments, Ltd. (Bendor), whose sole shareholder is Charles Stidham.&#160;&#160;The Company owes Mr. Stidham approximately $1,100,000, including accrued interest, as of the date of the Settlement Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company asserted a claim for management fees of approximately $80,000 and reimbursement of monies advanced to support the operations of the Stores totaling approximately $343,000 for the services of the Company&#146;s wholly-owned subsidiary, Medical Management Systems, Inc. (MMS), in managing the Stores.&#160;&#160;Bendor disputed this claim.&#160;&#160;To resolve the dispute, the parties agreed to forgive the accrued management fees and to offset the approximately $343,000 due from Bendor against the approximately $1,100,000 owed to Mr. Stidham with the Company releasing any and all interests it may have had in the Stores and MMS.&#160;&#160;Additionally, the Company agreed to assign a trademark to Mr. Stidham as well as executing a new Note in the principal sum of $752,694.19.&#160;&#160;The effect of the June 1, 2016 Settlement Agreement , due to the timing of this release of these amended financial statements and this transaction, is reflected in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the accrual basis of accounting in accordance with generally accepted accounting principles and has elected a year-end of December 31.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud.&#160;&#160;The Company&#146;s system of internal accounting control is designed to assure, among other items, that 1) recorded transactions are valid; 2) valid transactions are recorded; and 3) transactions are recorded in the proper period in a timely manner to produce financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During interim periods, the Company follows the accounting policies set forth in its annual audited financial statements filed with the U. S. Securities and Exchange Commission on its Annual Report on Form 10-K for the year ended December 31, 2015.&#160;&#160;The information presented within these interim financial statements may not include all disclosures required by accounting principles generally accepted in the United States of America and the users of financial information provided for interim periods should refer to the annual financial information and footnotes when reviewing the interim financial results presented herein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the opinion of management, the accompanying interim financial statements, prepared in accordance with the U. S.&#160;&#160;Securities and Exchange Commission&#146;s instructions for Form 10-Q, are unaudited and contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations and cash flows of the Company for the respective interim periods presented.&#160;&#160;The current period results of operations are not necessarily indicative of results which ultimately will be reported for the full fiscal year ending December 31, 2016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For segment reporting purposes, the Company operated in only one industry segment during the periods represented in the accompanying financial statements and makes all operating decisions and allocates resources based on the best benefit to the Company as a whole.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements, as of and for the periods ended March 31, 2016 and 2015, respectively, contain the accounts of MCPI, Inc.; its wholly-owned subsidiaries, Medical Management Systems, Inc., Med-Pharma Management, Inc., High Desert MMJ, Inc.; and it&#146;s majority-owned joint venture, Emerald Mountain Organics.&#160;&#160;All significant intercompany transactions have been eliminated.&#160;&#160;The consolidated entities are collectively referred to as &#147;Company&#148;.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 10pt">The Company was in the initial phases of providing back-office and support services to marijuana dispensaries and participates in a marijuana development and growing operation, all located in the State of Oregon.&#160;&#160;The dispensary operations under management by Medical Management Systems, Inc. began generating positive cash flows from operations during the 4</font><font style="font-size: 7pt">th</font><font style="font-size: 10pt"> quarter of 2015.&#160;&#160;However, management terminated the Medical Management Systems, Inc. Management Agreement on March 31, 2016 and wrote off all management fees (and deferred revenues) through that date.&#160;&#160;Further, the Company liquidated its Med-Pharma Management, Inc. and High Desert MMJ, Inc. subsidiaries as of March 31, 2016.&#160;&#160;All other efforts started by the Company and/or its subsidiaries in prior periods were either unsuccessful or abandoned.&#160;&#160;There is no assurance that the Company will be able to successful in the implementation or operation of its current business plan.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has limited operating history, limited cash on hand, no operating assets and has a business plan with inherent risk.&#160;&#160;Because of these factors, the Company&#146;s auditors have issued an audit opinion on the Company&#146;s financial statements which includes a statement describing our going concern status.&#160;&#160;This means, in the auditor&#146;s opinion, substantial doubt about our ability to continue as a going concern exists at the date of their opinion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of the Company's lack of operating assets, the Company&#146;s continuance may become fully dependent upon either future sales of securities and/or advances or loans from significant stockholders or corporate officers to provide sufficient working capital to preserve the integrity of the corporate entity during the development phase.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's continued existence is dependent upon its ability to implement its business plan, generate sufficient cash flows from operations to support its daily operations, and provide sufficient resources to retire existing liabilities and obligations on a timely basis.&#160;&#160;The Company faces considerable risk in it&#146;s business plan and a potential shortfall of funding due to our uncertainty to raise adequate capital in the equity securities market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is dependent upon existing cash balances to support its day-to-day operations.&#160;&#160;In the event that working capital sufficient to maintain the corporate entity and implement our business plan is not available, the Company&#146;s existing controlling stockholders intend to maintain the corporate status of the Company and provide all necessary working capital support on the Company's behalf.&#160;&#160;However, no formal commitments or arrangements to advance or loan funds to the Company or repay any such advances or loans exist.&#160;&#160;There is no legal obligation for either management or existing controlling stockholders to provide additional future funding. Further, the Company is at the mercy of future economic trends and business operations for the Company&#146;s existing controlling stockholders to have the resources available to support the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company anticipates offering future sales of equity securities.&#160;&#160;However, there is no assurance that the Company will be able to obtain additional funding through the sales of additional equity securities or, that such funding, if available, will be obtained on terms favorable to or affordable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s Articles of Incorporation authorizes the issuance of up to 25,000,000 million shares of preferred stock and 500,000,000 shares of common stock.&#160;&#160;The Company&#146;s ability to issue preferred stock may limit the Company&#146;s ability to obtain debt or equity financing as well as impede the implementation of the Company&#146;s business plan.&#160;&#160;The Company&#146;s ability to issue these authorized but unissued securities may also negatively impact our ability to raise additional capital through the sale of our debt or equity securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In such a restricted cash flow scenario, the Company would be unable to complete its business plan steps, and would, instead, delay all cash intensive activities.&#160;&#160;Without necessary cash flow, the Company may become dormant during the next twelve months, or until such time as necessary funds could be raised in the equity securities market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While the Company is of the opinion that good faith estimates of the Company&#146;s ability to secure additional capital in the future to reach its goals have been made, there is no guarantee that the Company will receive sufficient funding to sustain operations or implement any future business plan steps.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Cash and cash equivalents</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all cash on hand and in banks, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Organization costs</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted the provisions of provisions required by the Start-Up Activities topic of the FASB Accounting Standards Codification whereby all costs incurred with the incorporation and reorganization, post-bankruptcy, of the Company were charged to operations as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Revenue recognition</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recognized by the Company at the point at which a transaction is delivered or services are provided to a consumer at a fixed price, collection is reasonably assured, the Company has no remaining performance obligations and no right of return by the purchaser exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Income taxes</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the United States of America and various states, as appropriate and applicable.&#160;&#160;The Company is no longer subject to U.S. federal, state and local, as applicable, income tax examinations by regulatory taxing authorities for any period prior to January 1, 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the asset and liability method of accounting for income taxes.&#160;&#160;At March 31, 2016 and December 31, 2015, respectively, the deferred tax asset and deferred tax liability accounts, as recorded when material to the financial statements, are entirely the result of temporary differences.&#160;&#160;Temporary differences generally represent differences in the recognition of assets and liabilities for tax and financial reporting purposes, primarily accumulated depreciation and amortization, allowance for doubtful accounts and vacation accruals.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification.&#160;&#160;The Codification Topic requires the recognition of potential liabilities as a result of management&#146;s acceptance of potentially uncertain positions for income tax treatment on a &#147;more-likely-than-not&#148; probability of an assessment upon examination by a respective taxing authority.&#160;&#160;As a result of the implementation of Codification&#146;s Income Tax Topic, the Company did not incur any liability for unrecognized tax benefits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Income (Loss) per share</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the respective period presented in our accompanying financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fully diluted earnings (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of common stock equivalents (primarily outstanding options and warrants).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common stock equivalents represent the dilutive effect of the assumed exercise of the outstanding stock options and warrants, using the treasury stock method, at either the beginning of the respective period presented or the date of issuance, whichever is later, and only if the common stock equivalents are considered dilutive based upon the Company&#146;s net income (loss) position at the calculation date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2016 and 2015, respectively, the Company does not have any outstanding items which could be deemed to be dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>New and Pending Accounting Pronouncements</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is of the opinion that any and all other pending accounting pronouncements, either in the adoption phase or not yet required to be adopted, will not have a significant impact on the Company's financial position or results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amount of cash, accounts receivable, accounts payable and notes payable, as applicable, approximates fair value due to the short term nature of these items and/or the current interest rates payable in relation to current market conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest rate risk is the risk that the Company&#146;s earnings are subject to fluctuations in interest rates on either investments or on debt and is fully dependent upon the volatility of these rates.&#160;&#160;The Company does not use derivative instruments to moderate its exposure to interest rate risk, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial risk is the risk that the Company&#146;s earnings are subject to fluctuations in interest rates or foreign exchange rates and are fully dependent upon the volatility of these rates.&#160;&#160;The Company does not use derivative instruments to moderate its exposure to financial risk, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 28, 2014, the Company entered into a $500,000 Line of Credit note payable with South Beach Live, Ltd. (South Beach), a Company stockholder and an entity related to a significant Company stockholder, to provide funds necessary to support the corporate entity and provide working capital to pursue business combination or acquisition opportunities.&#160;&#160;This note bore interest at 10.0% and matured in July 2015.&#160;&#160;This note replaced a non-interest bearing shareholder note payable to a former controlling stockholder that was assumed during a 2014 change in control transaction.&#160;&#160;During the twelve months ended December 31, 2014, the Company recognized an aggregate $4,973 as additional paid-in capital for the economic event related to the non-interest bearing feature on the assumed note payable through its retirement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 30, 2015, the Company executed a replacement Promissory Note with the principal stockholder of South Beach Live, Ltd. in the amount of $927,000, bearing interest at 12.0% and payable in monthly installments of approximately $13,300, including accrued interest with a final maturity and balloon payment due on October 31, 2016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through March 31, 2016 and December 31, 2015, respectively, an aggregate of approximately $625,851 and $607,314, inclusive of the effect of the June 1, 2016 Settlement Agreement, as the lender continues to advance funds to support the Company&#146;s working capital needs.&#160;&#160;The Company is delinquent in making the required monthly installment payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The components of income tax (benefit) expense for the each of the three months ended March 31, 2016 and 2015, respectively, are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">T<b>hree months</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three months</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>ended</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>ended</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Federal:</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 72%; padding-left: 9pt"><font style="font: 10pt Times New Roman, Times, Serif">Current</font></td> <td style="width: 1%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font: 10pt Times New Roman, Times, Serif">Deferred</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">State:</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt"><font style="font: 10pt Times New Roman, Times, Serif">Current</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font: 10pt Times New Roman, Times, Serif">Deferred</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: 9pt">&#160;&#160;&#160;</font><font style="font: 10pt Times New Roman, Times, Serif">&#160;Total</font></td> <td style="padding-bottom: 3pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 3pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As of March 31, 2016, the Company had aggregate net operating loss carryforward(s) to offset future taxable income of approximately $1,100,000.&#160;&#160;&#160;The amount and availability of any net operating loss carryforward(s) will be subject to the limitations set forth in the Internal Revenue Code.&#160;&#160;Such factors as the number of shares ultimately issued within a three year look-back period; whether there is a deemed more than 50 percent change in control; the applicable long-term tax exempt bond rate; continuity of historical business; and subsequent income of the Company all enter into the annual computation of allowable annual utilization of any net operating loss carryforward(s).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's income tax (benefit) expense for the each of the three months ended March 31, 2016 and 2015, respectively, are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three months</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three months</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>ended</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>ended</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 72%"><font style="font: 10pt Times New Roman, Times, Serif">Statutory rate applied to income before income taxes</font></td> <td style="width: 1%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(14,000</font></td> <td nowrap="nowrap" style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(152,800</font></td> <td nowrap="nowrap" style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Increase (decrease) in income taxes resulting from:</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt"><font style="font: 10pt Times New Roman, Times, Serif">State income taxes</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt"><font style="font: 10pt Times New Roman, Times, Serif">Other, including reserve for deferred tax asset</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font: 10pt Times New Roman, Times, Serif">and application of net operating loss carryforward(s)</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">14,000</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">152,800</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: 9pt">&#160;&#160;&#160;</font><font style="font: 10pt Times New Roman, Times, Serif">&#160;Income tax expense</font></td> <td style="padding-bottom: 3pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 3pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Temporary differences, consisting primarily of the prospective usage of net operating loss carryforwards give rise to deferred tax assets and liabilities as of March 31, 2016 and December 31, 2015, respectively:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31,</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 72%; padding-left: 9pt"><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss carryforwards</font></td> <td style="width: 1%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">399,000</font></td> <td nowrap="nowrap" style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">385,000</font></td> <td nowrap="nowrap" style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><font style="font: 10pt Times New Roman, Times, Serif">Less valuation allowance</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(399,000</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(385,000</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 3pt"><font style="font: 10pt Times New Roman, Times, Serif; letter-spacing: 9pt">&#160;&#160;&#160;</font><font style="font: 10pt Times New Roman, Times, Serif">&#160;Net Deferred Tax Asset</font></td> <td style="padding-bottom: 3pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 3pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#151;</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2016 and for the year ended December 31, 2015, respectively, the valuation allowance against the deferred tax asset increased by approximately $14,000 and $251,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 23, 2016, the Company filed an amendment to its Articles of Incorporation stating &#147;After giving effect to a ten for one reverse split, Article III is amended to read as follows: The total number of shares of all classes of stock which the Corporation shall have the authority to issue is five hundred twenty five million (525,000,000) shares, of which five hundred million (500,000,000) shares, par value $0.001 per share, shall be designated as &#147;Common Stock&#148; and twenty five million (25,000,000) shares, par value $0.001 per share, shall be designated as &#147;Preferred Stock.&#148;&#160;&#160;The effect of this action is reflected in the accompanying financial statements as of the first day of the first period presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2015, the Company issued an aggregate of 50,000 shares for consulting services related to the provision of back-office and other management support services to marijuana dispensaries located in the State of Oregon.&#160;&#160;This stock was valued at $0.30 per share, which approximated the closing price on date of the issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended March 31, 2015, South Beach Live, Inc., a corporation controlled by a majority shareholder of the Company, transferred 1,000,000 shares of its holdings in the Company&#146;s common stock to consultants for ongoing services associated with marketing strategies.&#160;&#160;South Beach Live, Inc. is a related party and does not expect to be repaid for this transaction which was valued at approximately $300,000 and recorded as professional fees and contributed capital on the books of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue up to 25,000,000 shares of preferred stock, $0.001 par value.&#160;&#160;As of December 31, 2015, there are no shares of preferred stock issued and outstanding.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 10pt">On February 29, 2016, the Company filed a Definitive Information Statement on Schedule 14C with the Securities and Exchange Commission noting a pending 1 for 10 reverse split of the Company&#146;s issued and outstanding common stock; as approved by the Company&#146;s Board of Directors, and a concurrent amendment to the Company&#146;s Articles of Incorporation setting the authorized capital of the Company from the authorized, as adjusted, 25,000,000 post-split shares of common stock to 500,000,000 shares of $0.001 par value common stock and the authorized, as adjusted, 250,000 post-split shares of preferred stock to 25,000,000 shares of $0001 par value preferred stock.&#160;&#160;This action is anticipated to be completed during the 3</font><font style="font-size: 7pt">rd</font><font style="font-size: 10pt"> quarter of Calendar 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 1, 2016, the Company entered into a Settlement, General and Mutual Release of Claims and Assignment of Interest Transfer Agreement (Settlement Agreement) with its majority shareholder and a related party.&#160;&#160;The Settlement Agreement relates to the Company&#146;s management of three medical marijuana dispensaries (Stores) located in Oregon, which are owned by Bendor Investments, Ltd. (Bendor), whose sole shareholder is Charles Stidham.&#160;&#160;The Company owes Mr. Stidham approximately $1,100,000, including accrued interest, as of the date of the Settlement Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company asserted a claim for management fees of approximately $80,000 and reimbursement of monies advanced to support the operations of the Stores totaling approximately $343,000 for the services of the Company&#146;s wholly-owned subsidiary, Medical Management Systems, Inc. (MMS), in managing the Stores.&#160;&#160;Bendor disputed this claim.&#160;&#160;To resolve the dispute, the parties agreed to forgive the accrued management fees and to offset the approximately $343,000 due from Bendor against the approximately $1,100,000 owed to Mr. Stidham with the Company releasing any and all interests it may have had in the Stores and MMS.&#160;&#160;Additionally, the Company agreed to assign a trademark to Mr. Stidham as well as executing a new Note in the principal sum of $752,694.19.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated all other activity of the Company through the issue date of the financial statements and concluded that no subsequent events have occurred that would require recognition in the accompanying financial statements or disclosure in the Notes to Consolidated Financial Statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all cash on hand and in banks, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted the provisions of provisions required by the Start-Up Activities topic of the FASB Accounting Standards Codification whereby all costs incurred with the incorporation and reorganization, post-bankruptcy, of the Company were charged to operations as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recognized by the Company at the point at which a transaction is delivered or services are provided to a consumer at a fixed price, collection is reasonably assured, the Company has no remaining performance obligations and no right of return by the purchaser exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files income tax returns in the United States of America and various states, as appropriate and applicable.&#160;&#160;The Company is no longer subject to U.S. federal, state and local, as applicable, income tax examinations by regulatory taxing authorities for any period prior to January 1, 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the asset and liability method of accounting for income taxes.&#160;&#160;At March 31, 2016 and December 31, 2015, respectively, the deferred tax asset and deferred tax liability accounts, as recorded when material to the financial statements, are entirely the result of temporary differences.&#160;&#160;Temporary differences generally represent differences in the recognition of assets and liabilities for tax and financial reporting purposes, primarily accumulated depreciation and amortization, allowance for doubtful accounts and vacation accruals.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification.&#160;&#160;The Codification Topic requires the recognition of potential liabilities as a result of management&#146;s acceptance of potentially uncertain positions for income tax treatment on a &#147;more-likely-than-not&#148; probability of an assessment upon examination by a respective taxing authority.&#160;&#160;As a result of the implementation of Codification&#146;s Income Tax Topic, the Company did not incur any liability for unrecognized tax benefits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the respective period presented in our accompanying financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fully diluted earnings (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of common stock equivalents (primarily outstanding options and warrants).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common stock equivalents represent the dilutive effect of the assumed exercise of the outstanding stock options and warrants, using the treasury stock method, at either the beginning of the respective period presented or the date of issuance, whichever is later, and only if the common stock equivalents are considered dilutive based upon the Company&#146;s net income (loss) position at the calculation date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2016 and 2015, respectively, the Company does not have any outstanding items which could be deemed to be dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is of the opinion that any and all other pending accounting pronouncements, either in the adoption phase or not yet required to be adopted, will not have a significant impact on the Company's financial position or results of operations.</p> -14000 -152800 14000 152800 385000 399000 14000 251000 385000 399000 14763 10360 81816 105703 15000 50 14950 15000 300000 50000 18537 117000 EX-101.SCH 3 mcpi-20160331.xsd 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Background and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Preparation of Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going Concern Uncertainty link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Notes Payable to Stockholders link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Common Stock Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Notes Payable to Stockholders (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Income Taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Income Taxes (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 mcpi-20160331_cal.xml EX-101.DEF 5 mcpi-20160331_def.xml EX-101.LAB 6 mcpi-20160331_lab.xml Common Stock Equity Components [Axis] Additional Paid-In Capital Accumulated Deficit Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash and cash equivalents Total Current Assets Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable, Third parties Accrued expenses, Related party Accrued interest payable Related parties Note payable to stockholder Total Liabilities Commitments and Contingencies Stockholders' Equity (Deficit) Preferred stock - $0.001 par value 25,000,000 shares authorized, None issued and outstanding. Common stock - $0.001 par value, 500,000,000 shares authorized, 50,220,000 and 50,170,000 shares issued and outstanding Additional paid-in capital Accumulated deficit Total Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity (Deficit) Consolidated Balance Sheets Parenthetical Common stock, par value Common stock, shares authorized Common stock, shares outstanding Common stock, shares issued Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares outstanding Preferred stock, shares issued Consolidated Statements Of Operations And Comprehensive Loss Revenues Cost of Sales Gross Profit Operating expenses Professional fees General and administrative costs Depreciation and amortization Total operating expenses Loss from operations Other income (expense) Interest expense on notes payable to stockholder Loss before provision for income taxes Provision for income taxes Net loss Other comprehensive income Comprehensive loss Loss per weighted-average share of common stock outstanding, computed on net loss - basic and fully diluted Weighted-average number of shares of common stock outstanding - basic and fully diluted Statement [Table] Statement [Line Items] Biginning Balance, Amount Biginning Balance, Shares Issuance of common stock for consulting fees, Amount Issuance of common stock for consulting fees, Shares Contributed capital Net loss for the year Ending Balance, Amount Ending Balance, Shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Net income (loss) for the period Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization Common stock issued for professional fees Donated capital (Increase) Decrease in Accounts Receivable Accounts payable Accrued expenses Deferred revenues Net cash used in operating activities Cash Flows from Investing Activities Net cash used in investing activities Cash Flows from Financing Activities Cash received from notes payable to stockholders Net cash provided by financing activities Increase (Decrease) in Cash Cash at beginning of period Cash at end of period Supplemental Disclosure of Interest and Income Taxes Paid Interest paid during the period Income taxes paid during the period Supplemental Disclosure of Non-Cash Investing and Financing Activities Notes to Financial Statements Note A - Background and Description of Business Note B - Preparation of Financial Statements Note C - Going Concern Note D - Summary of Significant Accounting Policies Note E - Fair Value of Financial Instruments Note F - Notes Payable to Stockholders Note G - Income Taxes Note H - Common Stock Transactions Note I - Preferred Stock Note J - Subsequent Events Summary Of Significant Accounting Policies Policies Cash and Cash Equivalents Organization costs Revenue Recognition Income Taxes Income (Loss) per share New and Pending Accounting Pronouncements Income Taxes Tables Components of income tax (benefit) expense Schedule of deferred tax assets and liabilities Notes Payable To Stockholders Details Narrative Income Taxes Details Federal: Current Deferred Total State: Current Deferred Total Total Income Taxes Details 1 Statutory rate applied to income before income taxes Increase (decrease) in income taxes resulting from: State income taxes Other, including reserve for deferred tax asset and application of net operating loss carryforward(s) Income tax expense Income Taxes Details 2 Deferred tax assets Net operating loss carryforwards Less valuation allowance Net Deferred Tax Asset Income Taxes Details Narrative Loss carry-forwards Deferred tax asset valuation allowance Preferred Stock Details Narrative Assets, Current Assets Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Domestic Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Issued Depreciation Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Deferred State and Local Income Tax Expense (Benefit) State and Local Income Tax Expense (Benefit), Continuing Operations Deferred Tax Assets, Valuation Allowance EX-101.PRE 7 mcpi-20160331_pre.xml XML 8 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
Aug. 01, 2016
Document And Entity Information    
Entity Registrant Name MCPI, Inc.  
Entity Central Index Key 0001516559  
Document Type 10-Q  
Document Period End Date Mar. 31, 2016  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   50,220,000
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2016  
XML 9 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Balance Sheets - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Current Assets    
Cash and cash equivalents
Total Current Assets 0 0
Total Assets 0 0
Current Liabilities    
Accounts payable, Third parties 20,140 20,947
Accrued expenses, Related party 59,846 59,846
Accrued interest payable Related parties 105,703 81,816
Note payable to stockholder 685,851 607,314
Total Liabilities 811,540 769,923
Commitments and Contingencies
Stockholders' Equity (Deficit)    
Preferred stock - $0.001 par value 25,000,000 shares authorized, None issued and outstanding.
Common stock - $0.001 par value, 500,000,000 shares authorized, 50,220,000 and 50,170,000 shares issued and outstanding 50,220 50,220
Additional paid-in capital 59,336,620 59,336,620
Accumulated deficit (60,198,380) (60,156,763)
Total Stockholders' Equity (Deficit) (811,540) (769,923)
Total Liabilities and Stockholders' Equity (Deficit) $ 0 $ 0
XML 10 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2016
Dec. 31, 2015
Consolidated Balance Sheets Parenthetical    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares outstanding 50,220,000 50,170,000
Common stock, shares issued 50,220,000 50,170,000
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 25,000,000 25,000,000
Preferred stock, shares outstanding 0 0
Preferred stock, shares issued 0 0
XML 11 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Consolidated Statements Of Operations And Comprehensive Loss    
Revenues
Cost of Sales
Gross Profit
Operating expenses    
Professional fees 17,730 317,836
General and administrative costs 122,621
Depreciation and amortization
Total operating expenses 17,730 440,457
Loss from operations (17,730) (440,457)
Other income (expense)    
Interest expense on notes payable to stockholder (23,887) (8,815)
Loss before provision for income taxes (41,617) (449,272)
Provision for income taxes
Net loss (41,617) (449,272)
Other comprehensive income
Comprehensive loss $ (41,617) $ (449,272)
Loss per weighted-average share of common stock outstanding, computed on net loss - basic and fully diluted $ (0.00) $ (0.01)
Weighted-average number of shares of common stock outstanding - basic and fully diluted 50,220,000 50,206,111
XML 12 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Biginning Balance, Amount at Dec. 31, 2014 $ 50,170 $ 59,021,670 $ (59,418,274) $ (346,434)
Biginning Balance, Shares at Dec. 31, 2014 50,170,000      
Issuance of common stock for consulting fees, Amount $ 50 14,950 15,000
Issuance of common stock for consulting fees, Shares 50,000      
Contributed capital 300,000 300,000
Net loss for the year (738,488) (738,488)
Ending Balance, Amount at Dec. 31, 2015 $ 50,220 59,336,620 (60,156,762) (769,923)
Ending Balance, Shares at Dec. 31, 2015 50,220,000      
Issuance of common stock for consulting fees, Amount      
Net loss for the year (41,617) (41,617)
Ending Balance, Amount at Mar. 31, 2016 $ 50,220 $ 59,336,620 $ (60,198,380) $ (811,540)
Ending Balance, Shares at Mar. 31, 2016 50,220,000      
XML 13 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash Flows from Operating Activities    
Net income (loss) for the period $ (41,617) $ (449,272)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization
Common stock issued for professional fees 15,000
Donated capital 300,000
(Increase) Decrease in    
Accounts Receivable
Accounts payable 7,726
Accrued expenses 23,080 10,143
Deferred revenues (5,000)
Net cash used in operating activities (18,537) (121,403)
Cash Flows from Investing Activities    
Net cash used in investing activities
Cash Flows from Financing Activities    
Cash received from notes payable to stockholders 18,537 117,000
Net cash provided by financing activities 18,537 117,000
Increase (Decrease) in Cash (4,403)
Cash at beginning of period 14,763
Cash at end of period 10,360
Supplemental Disclosure of Interest and Income Taxes Paid    
Interest paid during the period
Income taxes paid during the period
Supplemental Disclosure of Non-Cash Investing and Financing Activities
XML 14 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Background and Description of Business
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note A - Background and Description of Business

MCPI, Inc. (“Company” or “Med-Cannabis Pharma”) was incorporated under the laws of the State of Nevada on February 23, 2011.  The Company was originally incorporated as Southwest China Imports, Inc. on February 23, 2011 in the State of Nevada.  The Company’s initial business plan was to import high-end handmade lace wigs, hairpieces, and other beauty supplies and accessories manufactured overseas into the United States.  In June 2014, the Company changed its name to Med-Cannabis Pharma, Inc. and implemented a new business plan to enter into the retail sale of medical and personal use  marijuana, where allowable.  In October 2015, the Company changed its name to MCPI, Inc.

 

Effective March 31, 2016, the Company ceased activities in all of its subsidiaries and disposed of Med-Pharma Management, Inc. and High Desert MMJ, Inc.  Prior thereto, the Company’s  subsidiaries were Medical Management Systems, Inc., an Oregon corporation engaged in providing back-office and support services to marijuana dispensaries in the State of Oregon; Med-Pharma Management, Inc., a Washington State corporation which was formed to own, manage or provide back-office and support services to marijuana dispensaries in Washington State; and High Desert MMJ, Inc. an Oregon corporation, which is a 99.0% partner in Emerald Mountain Organics, an Oregon joint venture, formed to facilitate the development and growing of medical marijuana plants for wholesale distribution to licenced dispensaries in the State of Oregon.

 

As of September 30, 2015, Medical Management Systems, Inc. held a Management Contract for three marijuana dispensaries located in Newport, Bend and Cottage Grove, Oregon; which are owned by a company controlled by a related party.  This Management Contract was terminated by the consent of both parties, effective March 31, 2016.   Med-Pharma only conducted introductory due diligence efforts in the State of Washington and, currently, had abandoned all activities in the State of Washington.  Emerald Mountain Organics had, as of September 30,2015, established an early-phase growing operation and has generated nominal sales.

 

During the first 10 days of October 2015, the Company’s subsidiary, High Desert MMJ, Inc., learned that the 1.0% minority partner in the Emerald Mountain Organics joint venture had absconded with all of the assets of the joint venture.  Efforts to locate and recover either the individuals representing said 1.0% minority partner or the said absconded assets were unsuccessful.  Accordingly, effective October 10, 2015, High Desert MMJ, Inc. abandoned the Emerald Mountain Organics joint venture and wrote off said investment.  The cumulative start-up losses in the Company’s consolidated financial statements for the Emerald Mountain Organics joint venture, through the date of abandonment were approximately $53,000 and the Company recognized a loss on the stolen assets of approximately $51,000 during the quarter ended December 31, 2015.

 

On June 1, 2016, the Company entered into a Settlement, General and Mutual Release of Claims and Assignment of Interest Transfer Agreement (Settlement Agreement) with its majority shareholder and a related party.  The Settlement Agreement relates to the Company’s management of three medical marijuana dispensaries (Stores) located in Oregon, which are owned by Bendor Investments, Ltd. (Bendor), whose sole shareholder is Charles Stidham.  The Company owes Mr. Stidham approximately $1,100,000, including accrued interest, as of the date of the Settlement Agreement.

 

The Company asserted a claim for management fees of approximately $80,000 and reimbursement of monies advanced to support the operations of the Stores totaling approximately $343,000 for the services of the Company’s wholly-owned subsidiary, Medical Management Systems, Inc. (MMS), in managing the Stores.  Bendor disputed this claim.  To resolve the dispute, the parties agreed to forgive the accrued management fees and to offset the approximately $343,000 due from Bendor against the approximately $1,100,000 owed to Mr. Stidham with the Company releasing any and all interests it may have had in the Stores and MMS.  Additionally, the Company agreed to assign a trademark to Mr. Stidham as well as executing a new Note in the principal sum of $752,694.19.  The effect of the June 1, 2016 Settlement Agreement , due to the timing of this release of these amended financial statements and this transaction, is reflected in the accompanying consolidated financial statements.

XML 15 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Preparation of Financial Statements
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note B - Preparation of Financial Statements

The Company follows the accrual basis of accounting in accordance with generally accepted accounting principles and has elected a year-end of December 31.

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

 

Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud.  The Company’s system of internal accounting control is designed to assure, among other items, that 1) recorded transactions are valid; 2) valid transactions are recorded; and 3) transactions are recorded in the proper period in a timely manner to produce financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

 

During interim periods, the Company follows the accounting policies set forth in its annual audited financial statements filed with the U. S. Securities and Exchange Commission on its Annual Report on Form 10-K for the year ended December 31, 2015.  The information presented within these interim financial statements may not include all disclosures required by accounting principles generally accepted in the United States of America and the users of financial information provided for interim periods should refer to the annual financial information and footnotes when reviewing the interim financial results presented herein.

 

In the opinion of management, the accompanying interim financial statements, prepared in accordance with the U. S.  Securities and Exchange Commission’s instructions for Form 10-Q, are unaudited and contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations and cash flows of the Company for the respective interim periods presented.  The current period results of operations are not necessarily indicative of results which ultimately will be reported for the full fiscal year ending December 31, 2016.

 

For segment reporting purposes, the Company operated in only one industry segment during the periods represented in the accompanying financial statements and makes all operating decisions and allocates resources based on the best benefit to the Company as a whole.

 

The accompanying consolidated financial statements, as of and for the periods ended March 31, 2016 and 2015, respectively, contain the accounts of MCPI, Inc.; its wholly-owned subsidiaries, Medical Management Systems, Inc., Med-Pharma Management, Inc., High Desert MMJ, Inc.; and it’s majority-owned joint venture, Emerald Mountain Organics.  All significant intercompany transactions have been eliminated.  The consolidated entities are collectively referred to as “Company”.

XML 16 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Going Concern Uncertainty
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note C - Going Concern

The Company was in the initial phases of providing back-office and support services to marijuana dispensaries and participates in a marijuana development and growing operation, all located in the State of Oregon.  The dispensary operations under management by Medical Management Systems, Inc. began generating positive cash flows from operations during the 4th quarter of 2015.  However, management terminated the Medical Management Systems, Inc. Management Agreement on March 31, 2016 and wrote off all management fees (and deferred revenues) through that date.  Further, the Company liquidated its Med-Pharma Management, Inc. and High Desert MMJ, Inc. subsidiaries as of March 31, 2016.  All other efforts started by the Company and/or its subsidiaries in prior periods were either unsuccessful or abandoned.  There is no assurance that the Company will be able to successful in the implementation or operation of its current business plan.

 

The Company has limited operating history, limited cash on hand, no operating assets and has a business plan with inherent risk.  Because of these factors, the Company’s auditors have issued an audit opinion on the Company’s financial statements which includes a statement describing our going concern status.  This means, in the auditor’s opinion, substantial doubt about our ability to continue as a going concern exists at the date of their opinion.

 

Because of the Company's lack of operating assets, the Company’s continuance may become fully dependent upon either future sales of securities and/or advances or loans from significant stockholders or corporate officers to provide sufficient working capital to preserve the integrity of the corporate entity during the development phase.

 

The Company's continued existence is dependent upon its ability to implement its business plan, generate sufficient cash flows from operations to support its daily operations, and provide sufficient resources to retire existing liabilities and obligations on a timely basis.  The Company faces considerable risk in it’s business plan and a potential shortfall of funding due to our uncertainty to raise adequate capital in the equity securities market.

 

The Company is dependent upon existing cash balances to support its day-to-day operations.  In the event that working capital sufficient to maintain the corporate entity and implement our business plan is not available, the Company’s existing controlling stockholders intend to maintain the corporate status of the Company and provide all necessary working capital support on the Company's behalf.  However, no formal commitments or arrangements to advance or loan funds to the Company or repay any such advances or loans exist.  There is no legal obligation for either management or existing controlling stockholders to provide additional future funding. Further, the Company is at the mercy of future economic trends and business operations for the Company’s existing controlling stockholders to have the resources available to support the Company.

 

The Company anticipates offering future sales of equity securities.  However, there is no assurance that the Company will be able to obtain additional funding through the sales of additional equity securities or, that such funding, if available, will be obtained on terms favorable to or affordable by the Company.

 

The Company’s Articles of Incorporation authorizes the issuance of up to 25,000,000 million shares of preferred stock and 500,000,000 shares of common stock.  The Company’s ability to issue preferred stock may limit the Company’s ability to obtain debt or equity financing as well as impede the implementation of the Company’s business plan.  The Company’s ability to issue these authorized but unissued securities may also negatively impact our ability to raise additional capital through the sale of our debt or equity securities.

 

In such a restricted cash flow scenario, the Company would be unable to complete its business plan steps, and would, instead, delay all cash intensive activities.  Without necessary cash flow, the Company may become dormant during the next twelve months, or until such time as necessary funds could be raised in the equity securities market.

 

While the Company is of the opinion that good faith estimates of the Company’s ability to secure additional capital in the future to reach its goals have been made, there is no guarantee that the Company will receive sufficient funding to sustain operations or implement any future business plan steps.

XML 17 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note D - Summary of Significant Accounting Policies

1.           Cash and cash equivalents

 

The Company considers all cash on hand and in banks, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents.

 

2.           Organization costs

 

The Company has adopted the provisions of provisions required by the Start-Up Activities topic of the FASB Accounting Standards Codification whereby all costs incurred with the incorporation and reorganization, post-bankruptcy, of the Company were charged to operations as incurred.

 

3.           Revenue recognition

 

Revenue is recognized by the Company at the point at which a transaction is delivered or services are provided to a consumer at a fixed price, collection is reasonably assured, the Company has no remaining performance obligations and no right of return by the purchaser exists.

 

4.           Income taxes

 

The Company files income tax returns in the United States of America and various states, as appropriate and applicable.  The Company is no longer subject to U.S. federal, state and local, as applicable, income tax examinations by regulatory taxing authorities for any period prior to January 1, 2011.

 

The Company uses the asset and liability method of accounting for income taxes.  At March 31, 2016 and December 31, 2015, respectively, the deferred tax asset and deferred tax liability accounts, as recorded when material to the financial statements, are entirely the result of temporary differences.  Temporary differences generally represent differences in the recognition of assets and liabilities for tax and financial reporting purposes, primarily accumulated depreciation and amortization, allowance for doubtful accounts and vacation accruals.

 

The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification.  The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority.  As a result of the implementation of Codification’s Income Tax Topic, the Company did not incur any liability for unrecognized tax benefits.

 

5.           Income (Loss) per share

 

Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the respective period presented in our accompanying financial statements.

 

Fully diluted earnings (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of common stock equivalents (primarily outstanding options and warrants).

 

Common stock equivalents represent the dilutive effect of the assumed exercise of the outstanding stock options and warrants, using the treasury stock method, at either the beginning of the respective period presented or the date of issuance, whichever is later, and only if the common stock equivalents are considered dilutive based upon the Company’s net income (loss) position at the calculation date.

 

As of March 31, 2016 and 2015, respectively, the Company does not have any outstanding items which could be deemed to be dilutive.

 

6.           New and Pending Accounting Pronouncements

 

The Company is of the opinion that any and all other pending accounting pronouncements, either in the adoption phase or not yet required to be adopted, will not have a significant impact on the Company's financial position or results of operations.

XML 18 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note E - Fair Value of Financial Instruments

The carrying amount of cash, accounts receivable, accounts payable and notes payable, as applicable, approximates fair value due to the short term nature of these items and/or the current interest rates payable in relation to current market conditions.

 

Interest rate risk is the risk that the Company’s earnings are subject to fluctuations in interest rates on either investments or on debt and is fully dependent upon the volatility of these rates.  The Company does not use derivative instruments to moderate its exposure to interest rate risk, if any.

 

Financial risk is the risk that the Company’s earnings are subject to fluctuations in interest rates or foreign exchange rates and are fully dependent upon the volatility of these rates.  The Company does not use derivative instruments to moderate its exposure to financial risk, if any.

XML 19 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Notes Payable to Stockholders
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note F - Notes Payable to Stockholders

On July 28, 2014, the Company entered into a $500,000 Line of Credit note payable with South Beach Live, Ltd. (South Beach), a Company stockholder and an entity related to a significant Company stockholder, to provide funds necessary to support the corporate entity and provide working capital to pursue business combination or acquisition opportunities.  This note bore interest at 10.0% and matured in July 2015.  This note replaced a non-interest bearing shareholder note payable to a former controlling stockholder that was assumed during a 2014 change in control transaction.  During the twelve months ended December 31, 2014, the Company recognized an aggregate $4,973 as additional paid-in capital for the economic event related to the non-interest bearing feature on the assumed note payable through its retirement.

 

On September 30, 2015, the Company executed a replacement Promissory Note with the principal stockholder of South Beach Live, Ltd. in the amount of $927,000, bearing interest at 12.0% and payable in monthly installments of approximately $13,300, including accrued interest with a final maturity and balloon payment due on October 31, 2016.

 

Through March 31, 2016 and December 31, 2015, respectively, an aggregate of approximately $625,851 and $607,314, inclusive of the effect of the June 1, 2016 Settlement Agreement, as the lender continues to advance funds to support the Company’s working capital needs.  The Company is delinquent in making the required monthly installment payments.

XML 20 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note G - Income Taxes

The components of income tax (benefit) expense for the each of the three months ended March 31, 2016 and 2015, respectively, are as follows:

 

    Three months     Three months  
    ended     ended  
    March 31,     March 31,  
    2016     2015  
Federal:            
Current   $     $  
Deferred            
             
State:                
Current            
Deferred            
             
                 
    Total   $     $  

 

As of March 31, 2016, the Company had aggregate net operating loss carryforward(s) to offset future taxable income of approximately $1,100,000.   The amount and availability of any net operating loss carryforward(s) will be subject to the limitations set forth in the Internal Revenue Code.  Such factors as the number of shares ultimately issued within a three year look-back period; whether there is a deemed more than 50 percent change in control; the applicable long-term tax exempt bond rate; continuity of historical business; and subsequent income of the Company all enter into the annual computation of allowable annual utilization of any net operating loss carryforward(s).

 

The Company's income tax (benefit) expense for the each of the three months ended March 31, 2016 and 2015, respectively, are as follows:

 

    Three months     Three months  
    ended     ended  
    March 31,     March 31,  
    2016     2015  
             
Statutory rate applied to income before income taxes   $ (14,000 )   $ (152,800 )
Increase (decrease) in income taxes resulting from:                
State income taxes            
Other, including reserve for deferred tax asset                
and application of net operating loss carryforward(s)     14,000       152,800  
                 
    Income tax expense   $     $  

 

Temporary differences, consisting primarily of the prospective usage of net operating loss carryforwards give rise to deferred tax assets and liabilities as of March 31, 2016 and December 31, 2015, respectively:

 

    March 31,     December 31,  
    2016     2015  
Deferred tax assets            
Net operating loss carryforwards   $ 399,000     $ 385,000  
Less valuation allowance     (399,000 )     (385,000 )
                 
    Net Deferred Tax Asset   $     $  

 

During the three months ended March 31, 2016 and for the year ended December 31, 2015, respectively, the valuation allowance against the deferred tax asset increased by approximately $14,000 and $251,000.

XML 21 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Common Stock Transactions
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note H - Common Stock Transactions

On March 23, 2016, the Company filed an amendment to its Articles of Incorporation stating “After giving effect to a ten for one reverse split, Article III is amended to read as follows: The total number of shares of all classes of stock which the Corporation shall have the authority to issue is five hundred twenty five million (525,000,000) shares, of which five hundred million (500,000,000) shares, par value $0.001 per share, shall be designated as “Common Stock” and twenty five million (25,000,000) shares, par value $0.001 per share, shall be designated as “Preferred Stock.”  The effect of this action is reflected in the accompanying financial statements as of the first day of the first period presented.

 

On January 15, 2015, the Company issued an aggregate of 50,000 shares for consulting services related to the provision of back-office and other management support services to marijuana dispensaries located in the State of Oregon.  This stock was valued at $0.30 per share, which approximated the closing price on date of the issuance.

 

During the period ended March 31, 2015, South Beach Live, Inc., a corporation controlled by a majority shareholder of the Company, transferred 1,000,000 shares of its holdings in the Company’s common stock to consultants for ongoing services associated with marketing strategies.  South Beach Live, Inc. is a related party and does not expect to be repaid for this transaction which was valued at approximately $300,000 and recorded as professional fees and contributed capital on the books of the Company.

XML 22 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Preferred Stock
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note I - Preferred Stock

The Company is authorized to issue up to 25,000,000 shares of preferred stock, $0.001 par value.  As of December 31, 2015, there are no shares of preferred stock issued and outstanding.

XML 23 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Subsequent Events
3 Months Ended
Mar. 31, 2016
Notes to Financial Statements  
Note J - Subsequent Events

On February 29, 2016, the Company filed a Definitive Information Statement on Schedule 14C with the Securities and Exchange Commission noting a pending 1 for 10 reverse split of the Company’s issued and outstanding common stock; as approved by the Company’s Board of Directors, and a concurrent amendment to the Company’s Articles of Incorporation setting the authorized capital of the Company from the authorized, as adjusted, 25,000,000 post-split shares of common stock to 500,000,000 shares of $0.001 par value common stock and the authorized, as adjusted, 250,000 post-split shares of preferred stock to 25,000,000 shares of $0001 par value preferred stock.  This action is anticipated to be completed during the 3rd quarter of Calendar 2016.

 

On June 1, 2016, the Company entered into a Settlement, General and Mutual Release of Claims and Assignment of Interest Transfer Agreement (Settlement Agreement) with its majority shareholder and a related party.  The Settlement Agreement relates to the Company’s management of three medical marijuana dispensaries (Stores) located in Oregon, which are owned by Bendor Investments, Ltd. (Bendor), whose sole shareholder is Charles Stidham.  The Company owes Mr. Stidham approximately $1,100,000, including accrued interest, as of the date of the Settlement Agreement.

 

The Company asserted a claim for management fees of approximately $80,000 and reimbursement of monies advanced to support the operations of the Stores totaling approximately $343,000 for the services of the Company’s wholly-owned subsidiary, Medical Management Systems, Inc. (MMS), in managing the Stores.  Bendor disputed this claim.  To resolve the dispute, the parties agreed to forgive the accrued management fees and to offset the approximately $343,000 due from Bendor against the approximately $1,100,000 owed to Mr. Stidham with the Company releasing any and all interests it may have had in the Stores and MMS.  Additionally, the Company agreed to assign a trademark to Mr. Stidham as well as executing a new Note in the principal sum of $752,694.19.

 

Management has evaluated all other activity of the Company through the issue date of the financial statements and concluded that no subsequent events have occurred that would require recognition in the accompanying financial statements or disclosure in the Notes to Consolidated Financial Statements.

XML 24 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2016
Summary Of Significant Accounting Policies Policies  
Cash and Cash Equivalents

The Company considers all cash on hand and in banks, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents.

Organization costs

The Company has adopted the provisions of provisions required by the Start-Up Activities topic of the FASB Accounting Standards Codification whereby all costs incurred with the incorporation and reorganization, post-bankruptcy, of the Company were charged to operations as incurred.

Revenue Recognition

Revenue is recognized by the Company at the point at which a transaction is delivered or services are provided to a consumer at a fixed price, collection is reasonably assured, the Company has no remaining performance obligations and no right of return by the purchaser exists.

Income Taxes

The Company files income tax returns in the United States of America and various states, as appropriate and applicable.  The Company is no longer subject to U.S. federal, state and local, as applicable, income tax examinations by regulatory taxing authorities for any period prior to January 1, 2011.

 

The Company uses the asset and liability method of accounting for income taxes.  At March 31, 2016 and December 31, 2015, respectively, the deferred tax asset and deferred tax liability accounts, as recorded when material to the financial statements, are entirely the result of temporary differences.  Temporary differences generally represent differences in the recognition of assets and liabilities for tax and financial reporting purposes, primarily accumulated depreciation and amortization, allowance for doubtful accounts and vacation accruals.

 

The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification.  The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority.  As a result of the implementation of Codification’s Income Tax Topic, the Company did not incur any liability for unrecognized tax benefits.

Income (Loss) per share

Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the respective period presented in our accompanying financial statements.

 

Fully diluted earnings (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of common stock equivalents (primarily outstanding options and warrants).

 

Common stock equivalents represent the dilutive effect of the assumed exercise of the outstanding stock options and warrants, using the treasury stock method, at either the beginning of the respective period presented or the date of issuance, whichever is later, and only if the common stock equivalents are considered dilutive based upon the Company’s net income (loss) position at the calculation date.

 

As of March 31, 2016 and 2015, respectively, the Company does not have any outstanding items which could be deemed to be dilutive.

New and Pending Accounting Pronouncements

The Company is of the opinion that any and all other pending accounting pronouncements, either in the adoption phase or not yet required to be adopted, will not have a significant impact on the Company's financial position or results of operations.

XML 25 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2016
Income Taxes Tables  
Components of income tax (benefit) expense

The components of income tax (benefit) expense for the each of the three months ended March 31, 2016 and 2015, respectively, are as follows:

 

    Three months     Three months  
    ended     ended  
    March 31,     March 31,  
    2016     2015  
Federal:            
Current   $     $  
Deferred            
             
State:                
Current            
Deferred            
             
                 
    Total   $     $  

 

The Company's income tax (benefit) expense for the each of the three months ended March 31, 2016 and 2015, respectively, are as follows:

 

    Three months     Three months  
    ended     ended  
    March 31,     March 31,  
    2016     2015  
             
Statutory rate applied to income before income taxes   $ (14,000 )   $ (152,800 )
Increase (decrease) in income taxes resulting from:                
State income taxes            
Other, including reserve for deferred tax asset                
and application of net operating loss carryforward(s)     14,000       152,800  
                 
    Income tax expense   $     $  
Schedule of deferred tax assets and liabilities

Temporary differences, consisting primarily of the prospective usage of net operating loss carryforwards give rise to deferred tax assets and liabilities as of March 31, 2016 and December 31, 2015, respectively:

 

    March 31,     December 31,  
    2016     2015  
Deferred tax assets            
Net operating loss carryforwards   $ 399,000     $ 385,000  
Less valuation allowance     (399,000 )     (385,000 )
                 
    Net Deferred Tax Asset   $     $  
XML 26 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Notes Payable to Stockholders (Details Narrative) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Notes Payable To Stockholders Details Narrative    
Note payable to stockholder $ 685,851 $ 607,314
XML 27 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes (Details) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Federal:    
Current
Deferred
Total
State:    
Current
Deferred
Total
Total
XML 28 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes (Details 1) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Income Taxes Details 1    
Statutory rate applied to income before income taxes $ (14,000) $ (152,800)
Increase (decrease) in income taxes resulting from:    
State income taxes
Other, including reserve for deferred tax asset and application of net operating loss carryforward(s) 14,000 152,800
Income tax expense
XML 29 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes (Details 2) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Deferred tax assets    
Net operating loss carryforwards $ 399,000 $ 385,000
Less valuation allowance (399,000) (385,000)
Net Deferred Tax Asset
XML 30 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Income Taxes Details Narrative    
Loss carry-forwards $ 1,100,000  
Deferred tax asset valuation allowance $ 14,000 $ 251,000
XML 31 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Preferred Stock (Details Narrative) - $ / shares
Mar. 31, 2016
Dec. 31, 2015
Preferred Stock Details Narrative    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 25,000,000 25,000,000
Preferred stock, shares outstanding 0 0
Preferred stock, shares issued 0 0
EXCEL 32 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 34 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 36 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 23 101 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://med-cannabispharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://med-cannabispharma.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://med-cannabispharma.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://med-cannabispharma.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Sheet http://med-cannabispharma.com/role/StatementOfChangesInStockholdersEquity Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://med-cannabispharma.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Background and Description of Business Sheet http://med-cannabispharma.com/role/BackgroundAndDescriptionOfBusiness Background and Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Preparation of Financial Statements Sheet http://med-cannabispharma.com/role/PreparationOfFinancialStatements Preparation of Financial Statements Notes 8 false false R9.htm 00000009 - Disclosure - Going Concern Uncertainty Sheet http://med-cannabispharma.com/role/Note2GoingConcern Going Concern Uncertainty Notes 9 false false R10.htm 00000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://med-cannabispharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Fair Value of Financial Instruments Sheet http://med-cannabispharma.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 11 false false R12.htm 00000012 - Disclosure - Notes Payable to Stockholders Notes http://med-cannabispharma.com/role/NotesPayableToStockholders Notes Payable to Stockholders Notes 12 false false R13.htm 00000013 - Disclosure - Income Taxes Sheet http://med-cannabispharma.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 00000014 - Disclosure - Common Stock Transactions Sheet http://med-cannabispharma.com/role/CommonStockTransactions Common Stock Transactions Notes 14 false false R15.htm 00000015 - Disclosure - Preferred Stock Sheet http://med-cannabispharma.com/role/PreferredStock Preferred Stock Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://med-cannabispharma.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://med-cannabispharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://med-cannabispharma.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Income Taxes (Tables) Sheet http://med-cannabispharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://med-cannabispharma.com/role/IncomeTaxes 18 false false R19.htm 00000019 - Disclosure - Notes Payable to Stockholders (Details Narrative) Notes http://med-cannabispharma.com/role/NotesPayableToStockholdersDetailsNarrative Notes Payable to Stockholders (Details Narrative) Details http://med-cannabispharma.com/role/NotesPayableToStockholders 19 false false R20.htm 00000020 - Disclosure - Income Taxes (Details) Sheet http://med-cannabispharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://med-cannabispharma.com/role/IncomeTaxesTables 20 false false R21.htm 00000021 - Disclosure - Income Taxes (Details 1) Sheet http://med-cannabispharma.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) Details http://med-cannabispharma.com/role/IncomeTaxesTables 21 false false R22.htm 00000022 - Disclosure - Income Taxes (Details 2) Sheet http://med-cannabispharma.com/role/IncomeTaxesDetails2 Income Taxes (Details 2) Details http://med-cannabispharma.com/role/IncomeTaxesTables 22 false false R23.htm 00000023 - Disclosure - Income Taxes (Details Narrative) Sheet http://med-cannabispharma.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://med-cannabispharma.com/role/IncomeTaxesTables 23 false false R24.htm 00000024 - Disclosure - Preferred Stock (Details Narrative) Sheet http://med-cannabispharma.com/role/PreferredStockDetailsNarrative Preferred Stock (Details Narrative) Details http://med-cannabispharma.com/role/PreferredStock 24 false false All Reports Book All Reports mcpi-20160331.xml mcpi-20160331.xsd mcpi-20160331_cal.xml mcpi-20160331_def.xml mcpi-20160331_lab.xml mcpi-20160331_pre.xml true true ZIP 38 0001165527-16-000850-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001165527-16-000850-xbrl.zip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